News & Events

Results of Operations and Financial Condition. On May 12, 2026, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Se…

Results of Operations and Financial Condition. On March 26, 2026, Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of…

Other Events. On December 19, 2025, Inhibikase Therapeutics, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), dated December 19, 2025, with respect to the Company’s existing “at the market offering” program (the “ATM Program”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $185,000,000, from time to time, throug…

Other Events. Effective November 20, 2025, the Company and the holders of all of the outstanding Series A-1 Warrants to Purchase Common Stock or Pre-Funded Warrants (each, a “Series A-1 Warrant”) and outstanding Series B-1 Warrants to Purchase Common Stock or Pre-Funded Warrants (each, a “Series B-1 Warrant”) issued on October 21, 2024, amended the terms of the Series A-1 Warrants (the “Amendment to Series A-1 Warrant”) and the Series B-1 Warrants (the “Amendment to Series B-1 Warrant”) to re…

Entry into a Material Definitive Agreement. On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock,…

Effective November 20, 2025, the Company terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333- 288213) and related to the shares of our common stock issuable pursuant to the Open Market Sale Agreement SM , dated June 20, 2025 (the “Sales Agreement”), by and between the Company and Jefferies LLC. As of the date hereof, the Company had not made any sales pursuant to the ATM Prospectus. Further, the Company wil…

Results of Operations and Financial Condition. On November 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpo…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference…

Results of Operations and Financial Condition. On May 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Se…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”). Mr. Lees-Rolfe’s resignation was not the result of any dispu…

Results of Operations and Financial Condition. On March 27, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of…

Entry into a Material Definitive Agreement. On February 21, 2025 (the “Closing Date”), Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Project IKT Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), CorHepta Pharmaceuticals, Inc., a Delaware corporation (“CorHepta”), and Preston S. Klassen, solely in his capacity as sellers’ repre…

by reference. The Consideration Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and the Company offered the Consideration Shares in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board appointed Chris Cabell as President and Head of Research and Development of the Company. The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board. Dr. Cabell, age 56…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Executive Officer, Principal Executive Officer and Director Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”)…

Other Events. On January 29, 2025, Inhibikase Therapeutics, Inc. (the “Company”) reported results from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. • The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50 mg, 100 mg, 200 mg or placebo for 12 weeks. The primary endpoints o…